MBX Biosciences, Inc.
MBX
$14.94
$1.057.56%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -22.41% | -93.56% | -76.25% | -78.51% | -108.43% |
Total Depreciation and Amortization | -3.17% | 60.42% | 41.46% | 87.50% | 61.54% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 97.62% | -54.15% | -76.95% | 4.46% | 487.21% |
Change in Net Operating Assets | -54.53% | 38.25% | 78.05% | 54.63% | 1,879.41% |
Cash from Operations | -31.38% | -111.75% | -43.88% | -89.80% | -79.79% |
Capital Expenditure | -56.42% | 89.01% | -67.27% | -159.09% | -1,358.06% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 458.83% | -79.26% | -132.71% | -442.06% | -137.20% |
Cash from Investing | 429.31% | -79.09% | -132.59% | -441.73% | -139.52% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 2,552.00% | -97.88% | 926.32% | 1,026,435.29% | -92.11% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -7.31% | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -7,223.33% | -- |
Cash from Financing | 175.30% | -97.81% | -794.74% | 244.27% | -377.76% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 143.09% | -496.74% | -108.36% | 185.45% | -273.36% |